Line Hartvig brings more than 20 years of experience from the pharma/biotech industry, working in drug discovery and nonclinical drug development. For more than 10 years, she has worked as an independent consultant for small and medium-size biotech companies. She also serves as an expert evaluator, e.g., at InnoExplorer, Innovationsfonden (Denmark), or EC _ SME /Horizon 2020 and IMI (EU).

From 2019 to 2020, she was CEO of RetiPharma. Prior to that, she worked as a Scientific Analyst at Sunstone Capital and as a Principal Scientist at Maxygen and Zealand Pharma, respectively. Earlier roles include Senior Scientist at AstraZeneca and H. Lundbeck. She also held positions as a PhD student at Novo Nordisk and Sct Hans Hospital.
Line Hartvig holds a PhD and an MSc in Biochemistry from the University of Copenhagen.

This website uses cookies to ensure you get the best experience on our website. Get more details by clicking on the Button below.